Qualifying Conditions
Current Conditions that Qualify for a Medicinal Cannabis Reccomendation:
- Autism Spectrum Disorder (ASD)
- Cancer-related cachexia, nausea or vomiting, weight loss, or chronic pain
- Crohn’s Disease
- Depression
- Epilepsy or a condition causing seizures
- HIV/AIDS-related nausea or weight loss
- Panic disorder
- Parkinson’s disease
- Persistent nausea that is not significantly responsive to traditional treatment, except for nausea related to pregnancy, cannabis-induced cyclical vomiting syndrome, or cannabinoid hyperemesis syndrome
- Post Traumatic Stress Disorder (PTSD)
- Sickle Cell Anemia
- Spasticity associated with a motor neuron disease, including Amyotrophic Lateral Sclerosis
- Spasticity associated with Multiple Sclerosis or a spinal cord injury
- Terminal illness
- Tourette’s Syndrome
- A condition causing chronic or intractable pain in which conventional therapeutic intervention and opiate therapy is contraindicated or has proved ineffective
* State law further requires recommending physicians to cite documentation indicating that “conventional medical treatment or therapy has failed” prior to issuing a medical cannabis recommendation.
Patient Possession Limits and Uses
Currently, patients of the Alabama Medicinal Cannabis Program are going to be allowed to possess up to a maximum of "70 daily doses" of medicinal cannabis at any given time. These doses are limited to 50 milligrams for the first 90 days. Current methods of approved consumption include "tablets, capsules, tinctures, or gel cubes for oral use; gels, oils or creams for topical use, or suppositories, transdermal patches, nebulizers, or liquids or oils for use in an inhaler." Alabama's medicinal program currently does not allow access to cannabis flower material or cannabis-infused edible products. Patients age 18 or younger are limited to low-THC cannabis products.